Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology”
Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics.
e-therapeutics has become the latest UK biotech to say it plans to delist from the Alternative Investment Market (AIM) in another blow to the reputation of the London Stoc
The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics.
Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emergin
The biopharma industry faces a relentless demand for evidence of real-world effectiveness (RWE), safety, and value throughout the product lifecycle to complement the clinical trial-based be
UK researchers say they have developed an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.